Ampullary Carcinoma

3

Review clinical trials related to Ampullary Carcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effect of Negative-Pressure Drainage Versus Pancreatic Duct Stenting for Preventing Pancreatitis After Endoscopic Papillectomy for Duodenal Papillary Tumors

This prospective, multicenter, randomized controlled trial aims to evaluate the effectiveness of negative-pressure duodenal drainage compared with prophylactic pancreatic duct stenting in preventing post-endoscopic papillectomy (EP) pancreatitis. Eligible patients undergoing EP will be randomized 1:1 to receive either negative-pressure drainage or pancreatic duct stenting. The primary outcome is the incidence of post-EP pancreatitis. Secondary outcomes include other procedure-related complications, procedure time, technical success, length of hospital stay, hospitalization cost, en-bloc and R0 resection rates, and postoperative hyperamylasemia.

Participants needed: 132
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Cui XiaobingUpdated: Mar 4, 2026
Eligibility criteria

Age between 18 and 75 years [+2]

Preoperative diagnosis suggestive of adenocarcinoma ≥T1b stage. [+6]

Status: Recruiting

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD). The study aims to determine the morbimortality of the laparoscopic approach compared to the gold standard open approach in adult patients with pancreatic or periampullary lesions.

Participants needed: 90
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Minia UniversityUpdated: Jan 21, 2026Locations: 1
Eligibility criteria

Age ≥18 years. [+5]

Emergency surgery. [+9]

Status: Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

A Phase Ⅱ, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With recurrent or metastatic ampulla tumors.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolUpdated: Oct 2, 2023
Eligibility criteria

Over 18 years old; [+8]

Patients who have previously been treated with small-molecule drugs similar to V... [+5]